Fibroblast growth factor 21 (FGF21), an emerging metabolic hepatokine, has been shown to exert beneficial effects on critical atherosclerotic pathways (2) and has been reported to be an independent predictor of subclinical atherosclerosis (3). This evidence concerns the gene FGF21 and atherosclerosis.